<DOC>
	<DOCNO>NCT02709668</DOCNO>
	<brief_summary>A randomized double-blind placebo control study reduce B vitamin patient major depression positive one common MTHFR polymorphism conduct 8/1/2014 4/3/2015 . Homocysteine level MADRS score use primary measure . The study design test safety efficacy reduce B vitamin MDD associate MTHFR . This study examine data trial see effect , effect size , , demographic factor patient characteristic correlate finding .</brief_summary>
	<brief_title>B Vitamins MTHFR Positive Patients With Major Depression : A Post Hoc Analysis Findings</brief_title>
	<detailed_description>This original study design evaluate efficacy safety reduce B vitamin monotherapy adult major depressive disorder ( MDD ) also positive least 1 methylenetetrahydrofolate reductase ( MTHFR ) polymorphism associate depression , test hypothesis reduce ( metabolize ) B vitamins low homocysteine ( HCY ) majority clinically respond patient . 330 adult patient MDD ( DSM-5 ) , positive MTHFR C677T and/or A1298C polymorphism enrol trial conduct August 1 , 2014 , April 3 , 2015 . 160 patient receive placebo , 170 receive capsule contain combination reduce B vitamin . Plasma homocysteine level measure baseline week 8 . The Montgomery-Asberg Depression Rating Scale ( MADRS ) use evaluate efficacy MDD . This analysis conduct resultant data , patient names withhold . It extensive look finding determine response correlate HCY reduction factor may associate response non-response .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<criteria>Major depression MTHFR positive status dementia , Bipolar , active substance abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>MTHFR depression vitamin Homocysteine</keyword>
</DOC>